AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04239196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV steroids combination alone
Description: Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
Study NCT00534417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
Study NCT00534417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
Study NCT00639977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
Study NCT00639977 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
Study NCT02057575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.01%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study NCT02057575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG324 Ophthalmic Solution 0.02%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study NCT02057575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study NCT02057575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost Ophthalmic Solution 0.005%
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study NCT04092049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lollipop
Description: chewing lollipop for 10 minutes
Study NCT03732976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ramped position
Description: This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
Study NCT03732976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramped position
Description: This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
Study NCT03548493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
Study NCT03548493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
Study NCT03548493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
Study NCT03548493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
Study NCT02876029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference
Description: the reference product used
Study NCT02876029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product
Description: The test Product used
Study NCT02906280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA needle
Description: tissue sampling
Study NCT02906280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA needle
Description: tissue sampling
Study NCT03578588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
Study NCT03662646 — intervention group
Intervention type: OTHER
Intervention: no intervention performed- observational only
Description: no intervention performed- observational only
Study NCT02066610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium and sodium selenate supplementation
Description: Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
Study NCT02066610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium and sodium selenite supplementation
Description: Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
Study NCT02066610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without selenium and sodium selenate supplementation
Description: Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
Study NCT02066610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without selenium and sodium selenite supplementation
Description: Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
Study NCT01003145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Study NCT00766402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol /acetaminophen
Description: Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
Study NCT00766402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
Study NCT01007006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMRDU
Description: The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
Study NCT03771222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic DLI
Description: The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
Study NCT01636583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSF water without meal
Description: Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
Study NCT01636583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LSF water and inhibitory meal
Description: Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
Study NCT01636583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fortified inhibitory meal with water
Description: Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-550
Description: 5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
Study NCT00550446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
Study NCT03943836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients in the music group will listen to classical music during their dental procedure.
Study NCT03807609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CON . control condition without exercise / rest condition
Description: Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03807609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX -30. Condition with an acute exercise set 30 minutes before lunch
Description: The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT03807609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX-180. condition with an acute exercise set 180 minutes before lunch
Description: The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT04052945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA acupuncture
Description: For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 ).
Study NCT04052945 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6).
Study NCT02182232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study NCT02182232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02182232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00301561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified follow-up approach of ARV treatment
Description: Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited
Study NCT00301561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up approach of ARV treatment
Description: Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed
Study NCT00458146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-093
Description: 60mg MM-093/week as a subcutaneous injection for 3 months
Study NCT00458146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MM-093
Description: 60mg MM-093/week as a subcutaneous injection for 3 months
Study NCT04374383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phthalocyanine Dye
Description: following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
Study NCT04374383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LASER assisted SRP
Description: LASER assisted SRP will be carried
Study NCT04374383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASER assisted SRP
Description: LASER assisted SRP will be carried
Study NCT01859611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriActive+ RF
Description: Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts.
Study NCT04614571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gluten Powder
Description: Administered orally daily for 14 days
Study NCT00687947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGRP
Description: CGRP (0.5 ug/min) infused intravenously over 20 min
Study NCT00687947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CGRP
Description: CGRP (0.5 ug/min) infused intravenously over 20 min
Study NCT03371745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trophectoderm biopsy
Description: Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
Study NCT03371745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreservation
Description: Rapid freezing using vitrification
Study NCT03371745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: Transfer of embryo that has been cultured in vitro into the uterus
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
Study NCT01896453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
Study NCT06538467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension exercise with inertial load
Description: Hip extension exercise with inertial load
Study NCT06538467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip extension exercise with gravitational load
Description: Hip extension exercise with gravitational load
Study NCT02780505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin c
Description: In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples.
Study NCT03996226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 oral tablets.
Study NCT02206737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nicotine e-cigarette
Study NCT02206737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose nicotine e-cigarette
Study NCT02206737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose nicotine e-cigarette
Study NCT04102488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Six-step hand hygiene technique with an application time of 30 seconds
Description: Six-step hand hygiene technique with an application time of 30 seconds
Study NCT04102488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Six-step hand hygiene technique with an application time of 15 seconds
Description: Six-step hand hygiene technique with an application time of 15 seconds
Study NCT04102488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-step hand hygiene technique with an application time of 30 seconds
Description: Three-step hand hygiene technique with an application time of 30 seconds
Study NCT04102488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-step hand hygiene technique with an application time of 15 seconds
Description: Three-step hand hygiene technique with an application time of 15 seconds
Study NCT02780505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement.
Study NCT00590525 — intervention group
Intervention type: PROCEDURE
Intervention: Cardioversion
Description: Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
Study NCT03427983 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hydrodissection
Description: Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.